Literature DB >> 1939251

Characterization of a cis-acting element required for efficient transcriptional activation of the collagen IV enhancer.

P D Burbelo1, L A Bruggeman, G C Gabriel, P E Klotman, Y Yamada.   

Abstract

Two regulatory regions in the murine collagen IV enhancer were identified. Transient transfection assays delimited a 210-base pair fragment within the first intron of the alpha 1(IV) collagen gene that had significant transcriptional enhancer activity. DNase I protection and gel mobility shift confirmed that two regions, designated footprints A and B, within this fragment bound nuclear factors. Gel shift studies suggested that the CCTTATCTCTGATGG motif (A-34) in the footprint A region was important for specific nuclear factor binding. Mutations in the A-34 motif abolished factor binding as detected by gel shift and resulted in a significant decrease in enhancer activity in transient transfection assays of F9 teratocarcinoma cells. Two putative transcription factors of Mr = 37,000 and Mr = 94,000, which interact with the A-34 motif, were purified from Engelbreth-Holm-Swarm tumor tissue using DEAE-Sephacel, heparin-Sepharose, salmon sperm DNA-Sepharose, and specific A-34 oligonucleotide affinity chromatography. Southwestern analysis revealed that both of these factors were capable of binding the A-34 oligonucleotide directly and did not require additional subunits for binding. These data suggest that positively acting transcription factor(s) interact with the A-34 site in the enhancer and are required for efficient transcription of the alpha 1 and alpha 2(IV) collagen chain genes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939251

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Genetic mapping of the alpha 1 and alpha 2 (IV) collagen genes to mouse chromosome 8.

Authors:  J D Filie; P D Burbelo; C A Kozak
Journal:  Mamm Genome       Date:  1995-07       Impact factor: 2.957

2.  Positive elements in the laminin gamma 1 gene synergize to activate high level transcription during cellular differentiation.

Authors:  H S Chang; N B Kim; S L Phillips
Journal:  Nucleic Acids Res       Date:  1996-04-01       Impact factor: 16.971

3.  Promoter of the canine tracheobronchial mucin gene.

Authors:  M Verma; V V Murthy; S Mathew; D Banerji; R N Kurl; M J Olnes; J R Yankaskas; C Blass; E A Davidson
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

4.  Elements within the beta-lactoglobulin gene inhibit expression of human serum albumin cDNA and minigenes in transfected cells but rescue their expression in the mammary gland of transgenic mice.

Authors:  I Barash; M Nathan; R Kari; N Ilan; M Shani; D R Hurwitz
Journal:  Nucleic Acids Res       Date:  1996-02-15       Impact factor: 16.971

5.  SRY-related HMG box 9 regulates the expression of Col4a2 through transactivating its enhancer element in mesangial cells.

Authors:  Eriko Sumi; Noriyuki Iehara; Haruhiko Akiyama; Takeshi Matsubara; Akira Mima; Hiroshi Kanamori; Atsushi Fukatsu; David J Salant; Toru Kita; Hidenori Arai; Toshio Doi
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

6.  Expression of laminin gamma 1 cultured hepatocytes involves repeated CTC and GC elements in the LAMC1 promoter.

Authors:  F Levavasseur; J Liétard; K Ogawa; N Théret; P D Burbelo; Y Yamada; A Guillouzo; B Clément
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

7.  Multiple negative elements in a gene that codes for an extracellular matrix protein, collagen X, restrict expression to hypertrophic chondrocytes.

Authors:  P Lu Valle; M Iwamoto; P Fanning; M Pacifici; B R Olsen
Journal:  J Cell Biol       Date:  1993-06       Impact factor: 10.539

8.  A myelin proteolipid protein-LacZ fusion protein is developmentally regulated and targeted to the myelin membrane in transgenic mice.

Authors:  P A Wight; C S Duchala; C Readhead; W B Macklin
Journal:  J Cell Biol       Date:  1993-10       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.